One of the primary factors contributing to cancer cells' resistance to anti-tumor treatments is the activation of signalling pathways including NF-κB, PI3K/AkT/mTOR, JAK/STAT, MAPK, Wnt/β-Catenin and Notch signaling Pathways. This evidence concerns the gene AKT1 and neoplasm.